Literature DB >> 22460183

IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.

Claudio Pozzi1, Simeone Andrulli, Antonello Pani, Patrizia Scaini, Dario Roccatello, Giambattista Fogazzi, Paola Pecchini, Roberto Rustichelli, Pietro Finocchiaro, Lucia Del Vecchio, Francesco Locatelli.   

Abstract

BACKGROUND: Therapeutic nihilism is common in IgA nephropathy (IgAN) and renal insufficiency.
METHODS: In a randomized controlled trial comparing steroids alone or combined with azathioprine in 253 IgAN patients, we used a separate randomization list for patients with creatinine >2.0 mg/dL. Twenty patients (group 1) were randomized to 3 intravenous pulses of methylprednisolone 1 g at months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for 6 months, followed by oral prednisone 0.2 mg/kg every other day plus azathioprine 50 mg/day for a further 6 months; 26 patients (group 2) received steroids alone. The primary outcome was renal survival (50% increase in plasma creatinine from baseline); secondary outcomes were proteinuria over time and adverse events.
RESULTS: Six-year renal survival was not different between the 2 groups (50% vs. 57%; log-rank p=0.34). Median proteinuria decreased during follow-up in the whole population (from 2.45 g/day [interquartile range (IQR) 1.50-3.78] to 1.09 g/day [IQR 0.56- 2.46]; p<0.001), with no between-group difference. Multivariate predictors associated with renal survival were sex of patient, proteinuria during follow-up, number of antihypertensive drugs, angiotensin-converting enzyme inhibitors and treatment including azathioprine. Six patients in group 1 (30%) and 4 in group 2 (15%) did not complete the therapy, because of side effects (p=0.406).
CONCLUSIONS: Six-year renal survival was similar in the 2 groups. At Cox analysis the addition of azathioprine may be slightly more effective than corticosteroids alone in patients with chronic renal insufficiency, although with an increase of side effects.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22460183     DOI: 10.5301/jn.5000110

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  28 in total

Review 1.  IgA Nephropathy.

Authors:  Jennifer C Rodrigues; Mark Haas; Heather N Reich
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 8.237

2.  GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.

Authors:  Lesley A Inker; Hiddo J L Heerspink; Hocine Tighiouart; Andrew S Levey; Josef Coresh; Ron T Gansevoort; Andrew L Simon; Jian Ying; Gerald J Beck; Christoph Wanner; Jürgen Floege; Philip Kam-Tao Li; Vlado Perkovic; Edward F Vonesh; Tom Greene
Journal:  J Am Soc Nephrol       Date:  2019-07-10       Impact factor: 10.121

3.  Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial.

Authors:  Kosuke Masutani; Akihiro Tsuchimoto; Tomomi Yamada; Makoto Hirakawa; Koji Mitsuiki; Ritsuko Katafuchi; Hideki Hirakata; Takanari Kitazono; Kazuhiko Tsuruya
Journal:  Clin Exp Nephrol       Date:  2016-01-13       Impact factor: 2.801

Review 4.  [Pathophysiology and treatment of IgA nephropathy].

Authors:  R Bollin; H Haller
Journal:  Internist (Berl)       Date:  2018-07       Impact factor: 0.743

5.  Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.

Authors:  Feng Ma; Xiaoxia Yang; Meilan Zhou; Ming Bai; Lijuan Zhao; Li Li; Ruijuan Dong; Chunmei Liu; Rong Li; Shiren Sun
Journal:  J Nephrol       Date:  2020-05-23       Impact factor: 3.902

6.  Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience.

Authors:  Heyan Wu; Xiang Fang; Zhengkun Xia; Chunlin Gao; Yingchao Peng; Xiaojie Li; Pei Zhang; Qianghuining Kuang; Ren Wang; Meiqiu Wang
Journal:  J Nephrol       Date:  2020-06-07       Impact factor: 3.902

Review 7.  Treatment of IgA nephropathy.

Authors:  Claudio Pozzi
Journal:  J Nephrol       Date:  2015-11-17       Impact factor: 3.902

Review 8.  Treatment of IgA nephropathy with renal insufficiency.

Authors:  Claudio Pozzi; Cristina Sarcina; Francesca Ferrario
Journal:  J Nephrol       Date:  2016-01-07       Impact factor: 3.902

9.  Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy.

Authors:  Cristina Sarcina; Carmine Tinelli; Francesca Ferrario; Antonello Pani; Annalisa De Silvestri; Patrizia Scaini; Lucia Del Vecchio; Elena Alberghini; Laura Buzzi; Ivano Baragetti; Claudio Pozzi
Journal:  Clin J Am Soc Nephrol       Date:  2016-04-29       Impact factor: 8.237

Review 10.  Corticosteroids in IgA Nephropathy: Lessons from Recent Studies.

Authors:  Rosanna Coppo
Journal:  J Am Soc Nephrol       Date:  2016-09-26       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.